TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation

Non-genotoxic reactivation of the p53 pathway by MDM2-p53 binding antagonists is an attractive treatment strategy for wild-type TP53 cancers. To determine how resistance to MDM2/p53 binding antagonists might develop, SJSA-1 and NGP cells were exposed to growth inhibitory concentrations of chemically...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Drummond, Catherine J., Esfandiari, Arman, Liu, Junfeng, Lu, Xiaohong, Hutton, Claire, Jackson, Jennifer, Bennaceur, Karim, Xu, Qing, Makimanejavali, Aditya Rao, Bello, Fabio Del, Piergentili, Alessandro, Newell, David R., Hardcastle, Ian R., Griffin, Roger J., Lunec, John
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2016
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5216791/
https://ncbi.nlm.nih.gov/pubmed/27323823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10073
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller